Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles

Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles

Abstract Severe, protracted symptoms are associated with poor outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In a placebo-controlled study of casirivimab and imdevimab (CAS + IMD) in persons at high risk of severe coronavirus disease 2019 (COVID-19; n = 3816), ev...

Full description

Bibliographic Details
Main Authors: Dateng Li, Meng Xu, Andrea T. Hooper, Diana Rofail, Kusha A. Mohammadi, Yiziying Chen, Shazia Ali, Thomas Norton, David M. Weinreich, Bret J. Musser, Jennifer D. Hamilton, Gregory P. Geba
Format: Article
Language:English
Published: Nature Portfolio 2023-08-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-39681-7

Internet

https://doi.org/10.1038/s41598-023-39681-7

Similar Items